Shin Nippon Biomedical Laboratories, Ltd.

Headquartered in Tokyo, Japan, SNBL is a leading global preclinical and early-stage clinical contract research services provider and creator of innovative therapeutic technologies, including the proprietary dry-powder nasal formulation and drug delivery device technologies incorporated in Satsuma’s lead product candidate, STS101, and the stereopure nucleic acid therapeutic technology being developed by SNBL spinout company, WAVE Life Sciences (NASDAQ:WVE).